Similar findings have been observed with CD133 mRNA-loaded DC vaccination in humanized glioma models [232], CD44-loaded DCs in colorectal cancer [233], and different other approaches that might be based on DCs, T cells, and oncolytic viruses [234,235,236]. This evidence concerns the gene CD44 and colorectal cancer.